Tevogen receives initial $2M grant, may receive $8M more at future date

Tevogen (TVGN) announced it may receive up to $10M of non-dilutive grant funding. Tevogen Bio signed a grant agreement with KRHP, receiving an initial contribution of $2M. An additional $8M may be contributed at a future date, contingent on KRHP’s review of the company’s activities. The grant is intended to further Tevogen Bio’s mission to develop T cell therapeutics addressing the significant unmet needs of large patient populations for treatment of cancers and viral infections. KRHP is affiliated with an existing Tevogen investor. The receipt of the grant was not dilutive to existing Tevogen Bio shareholders.